NCT05737433View on ClinicalTrials.gov

Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

May 1, 2023

Study Completion Date

August 4, 2023

Conditions
NASH With Fibrosis
Interventions
DRUG

[14C]-rencofilstat 225mg

radio-labelled 225mg oral dose of rencofilstat

Trial Locations (1)

Unknown

Quotient Sciences, Nottingham

Sponsors
All Listed Sponsors
lead

Hepion Pharmaceuticals, Inc.

INDUSTRY